A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy | Zendy

Hugh D. Allen | Zendy; Kevin M. Flanigan | Zendy; Philip T. Thrush | Zendy; Igor Dvorchik | Zendy; Han Yin | Zendy; Charles E. Canter | Zendy; Anne M. Connolly | Zendy; Mark D. Parrish | Zendy; Craig M. McDonald | Zendy; Elizabeth Braunlin | Zendy; Steven D. Colan | Zendy; John Day | Zendy; Basil T. Darras | Zendy; Jerry R. Mendell | Zendy

Open Access

A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy

Author(s) -

Hugh D. Allen,

Kevin M. Flanigan,

Philip T. Thrush,

Igor Dvorchik,

Han Yin,

Charles E. Canter,

Anne M. Connolly,

Mark D. Parrish,

Craig M. McDonald,

Elizabeth Braunlin,

Steven D. Colan,

John Day,

Basil T. Darras,

Jerry R. Mendell

Publication year - 2013

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.md.2cc69a1dae4be7dfe2bcb420024ea865

Subject(s) - lisinopril , medicine , duchenne muscular dystrophy , losartan , ejection fraction , dystrophin , muscular dystrophy , cardiology , cardiomyopathy , angiotensin converting enzyme , heart failure , angiotensin ii , blood pressure

This study sought to compare the effectiveness and safety of an angiotensin converting enzyme inhibitor (ACE-I) (lisinopril) vs. an angiotensin receptor blocker (ARB) (losartan) for the treatment of cardiomyopathy (CM) in boys with Duchenne muscular dystrophy (DMD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research